Coverage
Filings
| Filing | Date |
|---|---|
| Blenrep approved in the EU for multiple myeloma | 24 Jul 2025 |
| Transaction in Own Shares | 23 Jul 2025 |
| US FDA review extended for Blenrep | 23 Jul 2025 |
| Transaction in Own Shares | 22 Jul 2025 |
| Transaction in Own Shares | 21 Jul 2025 |
| Blenrep US ODAC outcome | 18 Jul 2025 |
| Transaction in Own Shares | 18 Jul 2025 |
| Director/PDMR Shareholding | 18 Jul 2025 |
| GSK’s Shingrix Fully Liquid FDA approval |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 17 Jul 2025 |
| Transaction in Own Shares | 17 Jul 2025 |
| Transaction in Own Shares | 16 Jul 2025 |
| Director/PDMR Shareholding | 15 Jul 2025 |